Sugi Predict

Sugi Predict / Compounds / SCHEMBL1241273

SCHEMBL1241273

SCHEMBL1241273

NC(=O)CNC(=O)c1ncccc1OC[C@H]1CCCN1C(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CCR2 P41597 7/20 0.42
▸ TLR7 Q9NYK1 2/20 0.41
▸ TRPV1 Q8NER1 1/20 0.41
▸ KCNH2 Q12809 1/20 0.40
▸ MRGPRX4 Q96LA9 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TACR1 P25103 1/20 0.40
▸ KMT2A Q03164 1/20 0.39
▸ VNN1 O95497 1/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.39
▸ GRIN2C Q14957 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1241275 1.00 CCR2 (0.42) CCR2TLR7TRPV1KCNH2MRGPRX4
SCHEMBL9102502 0.90 SCD (0.43) CCR2TLR7TRPV1MRGPRX4ALDH1A1
SCHEMBL9102506 0.90 SCD (0.43) CCR2TLR7TRPV1MRGPRX4ALDH1A1
SCHEMBL1241640 0.89 TRPV1 (0.44) TLR7TRPV1ALDH1A1LMNAKMT2A
SCHEMBL1241642 0.89 TRPV1 (0.44) TLR7TRPV1ALDH1A1LMNAKMT2A
SCHEMBL1241570 0.88 HRH3 (0.46) TRPV1MRGPRX4LMNATACR1VNN1
SCHEMBL1241568 0.88 HRH3 (0.46) TRPV1MRGPRX4LMNATACR1VNN1
SCHEMBL1240264 0.88 ALDH1A1 (0.42) TLR7TRPV1MRGPRX4ALDH1A1LMNA
SCHEMBL1240267 0.88 ALDH1A1 (0.42) TLR7TRPV1MRGPRX4ALDH1A1LMNA
SCHEMBL1241560 0.88 SORT1 (0.43) TLR7TRPV1ALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969383-B2 Picolinamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-03-03 — — US disclosed
US-8969383-B2 Picolinamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-03-03 — — US disclosed
US-20140296237-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2014-10-02 — — US disclosed
US-20140296237-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2014-10-02 — — US disclosed
US-8809380-B2 Picolinamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2014-08-19 — — US disclosed
US-8809380-B2 Picolinamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2014-08-19 — — US disclosed
US-20120142691-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. 2012-06-07 — — US disclosed
US-20120142691-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. 2012-06-07 — — US disclosed
WO-2011016234-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2011-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142691-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS CACNA1G, SCN3A, SCN5A CCR2 4510/4885TLR7 4026/4885TRPV1 13/4885
US-20140296237-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS CACNA1G, SCN3A, SCN5A CCR2 4510/4885TLR7 4026/4885TRPV1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.